BioCryst Expands into Rare Swelling Disease
BioCryst has made a deal valuing its stock at $700 million to acquire Astria, gaining a long-acting injectable for hereditary angioedema.
Hereditary angioedema is a rare but competitive area of drug research, with multiple marketed medicines available to prevent or treat symptoms.
- BioCryst's current business is built around Orladeyo, a once-daily pill to ward off swelling attacks.
- Orladeyo generated $438 million in revenue last year, with expected net revenue up to $600 million in 2025.
Hereditary angioedema has become a very competitive area of drug research.
BioCryst's deal complements its daily pill with a long-acting injectable, strengthening its position in the market.
Author's summary: BioCryst expands into hereditary angioedema treatment.
More News
- DA outraged by brutal Mpumalanga farm attack
- America has already seen more than 300 mass shootings in 2025, data shows
- ADB Supports Uzbekistan’s Economic Transformation and Global Trade Integration
- In Marc Maron's last 'WTF' podcast episode, Obama offers advice on closing chapters
- Tre Johnson Scores 10 in First NBA Preseason Start - Lake Highlands
- Sociable old pirate going in races Crossword Clue - Try Hard Guides
- We should all find a way to express our gratitude
- Are Twiggy Forrest’s green goals uneconomic or has China bounced him? - Switzer Daily